Precigen, Inc. (PGEN): Price and Financial Metrics
PGEN Stock Summary
- With a price/sales ratio of 14.49, Precigen Inc has a higher such ratio than 86.7% of stocks in our set.
- PGEN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 79.06% of US stocks.
- With a year-over-year growth in debt of -26.48%, Precigen Inc's debt growth rate surpasses only 13.79% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Precigen Inc, a group of peers worth examining would be TUFN, LC, BGMD, STXS, and WK.
- PGEN's SEC filings can be seen here. And to visit Precigen Inc's official web site, go to www.precigen.com.
PGEN Stock Price Chart Interactive Chart >
PGEN Price/Volume Stats
| Current price | $7.48 | 52-week high | $11.10 |
| Prev. close | $7.27 | 52-week low | $2.14 |
| Day low | $7.23 | Volume | 325,087 |
| Day high | $7.64 | Avg. volume | 1,671,841 |
| 50-day MA | $8.00 | Dividend yield | N/A |
| 200-day MA | $6.55 | Market Cap | 1.54B |
Precigen, Inc. (PGEN) Company Bio
Precigen, Inc. (formerly Intrexon Corporation) provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. The company was founded in 1998 and is based in Germantown, Maryland.
Latest PGEN News From Around the Web
Below are the latest news stories about Precigen Inc that investors may wish to consider to help them evaluate PGEN as an investment opportunity.
Precigen Announces Departure of Chief Financial OfficerPrecigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that by mutual agreement Rick Sterling is stepping down from his position as Chief Financial Officer effective April 2, 2021. Precigen has commenced an executive search for a successor with the qualifications to contribute to Precigen's accelerating growth from a clinical stage company to a commercial organization. |
How Much Of Precigen, Inc. (NASDAQ:PGEN) Do Insiders Own?Every investor in Precigen, Inc. ( NASDAQ:PGEN ) should be aware of the most powerful shareholder groups. Institutions... |
Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy for recurrent respiratory papillomatosis (RRP). In January 2021, Precigen announced the clearance of the IND to Initiate a Phase I study of PRGN-2012 AdenoVerse™ immunotherapy in adult patients with RRP (clinical trial identifier: NCT04724980). PRGN-2012 is under development through a Cooperative Research and Development Agreement (CRADA) with the Center for Cancer Research (CCR) at the National Cancer Institute (NCI), which is part of the Natio... |
Precigen Reports Fourth Quarter and Full Year 2020 Financial ResultsPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2020 financial results. |
Precigen, Inc. to Host Earnings CallNEW YORK, NY / ACCESSWIRE / March 1, 2021 / Precigen, Inc. (NASDAQ:PGEN) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 1, 2021 at 4:30 PM Eastern Time. |
PGEN Price Returns
| 1-mo | -15.86% |
| 3-mo | -6.62% |
| 6-mo | 54.87% |
| 1-year | 175.00% |
| 3-year | -60.34% |
| 5-year | -80.30% |
| YTD | -26.67% |
| 2020 | 86.13% |
| 2019 | -16.21% |
| 2018 | -43.23% |
| 2017 | -52.59% |
| 2016 | -19.40% |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...